Mykytiv Vitaliy, Alwaheed Abrar, Mohd Hashim Nurul Asyikin
Haematology Department, Cork University Hospital, Cork, Ireland.
Hematol Oncol Stem Cell Ther. 2019 Mar;12(1):64-66. doi: 10.1016/j.hemonc.2017.08.003. Epub 2017 Oct 18.
The standard diagnosis of multiple myeloma by flow cytometry is based on selection of population of CD38/CD138 positives cells. As the result treatment with proteasome inhibitors, CD138 may be underexpressed on atypical plasma cells. Thus, in order to improve this strategy, recently new CD138-independent method, based on CD38 positivity of plasma cells was developed. We present an unusual case of CD138 negative multiple myeloma which had become double CD138/CD38 negative after treatment with daratumumab by which we would like to illustrate potential pitfalls of both strategies.
通过流式细胞术对多发性骨髓瘤进行标准诊断是基于选择CD38/CD138阳性细胞群体。由于蛋白酶体抑制剂治疗的结果，CD138可能在非典型浆细胞上表达不足。因此，为了改进这一策略，最近开发了一种基于浆细胞CD38阳性的新型非CD138依赖方法。我们报告了一例不寻常的CD138阴性多发性骨髓瘤病例，该病例在用达雷妥尤单抗治疗后变为CD138/CD38双阴性，我们希望借此说明这两种策略的潜在缺陷。
